Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Paradigm Biopharmaceuticals receives US FDA feedback on IND application for PPS in knee OA

% of readers think this story is Fact. Add your two cents.


Paradigm Biopharmaceuticals Ltd (ASX:PAR) (OTCMKTS:PBIGF) has received written feedback from the US Food and Drug Administration (FDA) regarding the investigational new drug (IND) submission for its pivotal study evaluating Pentosan Polysulfate Sodium (PPS) in knee OA.

The agency’s feedback contained its positions and questions principally in relation to recently completed non-clinical studies.

US FDA also provided suggested mitigation strategies to address its positions and questions, which included further detailed clinical monitoring.

Response within 30 days

Paradigm’s responses to the FDA questions will include mitigation strategies consistent with the FDA’s suggestions as well as clarification of existing study data.

The company is on track to submit its complete response to the agency within 30 days.

A review and response from the FDA will then be due within 30 days of the receipt of Paradigm’s response.

IND submission

The IND submission includes reports on the phase 1 study in healthy volunteers completed in quarter four of 2020 as well as several non-clinical studies that detail the pharmacokinetics and toxicology of PPS.

It also describes the GMP manufacture of the active substance and the drug product used for the pivotal phase 3 studies.

Once the IND is ‘Open’ the company may begin recruitment and screening of participants for the study.

Phase 3 study preparation

In parallel, Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia.

Additional sites may be added in order to ensure completion of this pivotal study, within the planned commercialisation timelines.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/950375/paradigm-biopharmaceuticals-receives-us-fda-feedback-on-ind-application-for-pps-in-knee-oa-950375.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.